Cisplatin encapsulation

Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anti-Cancer Drugs 1999 10 911-920. 

Newman, M. S., Colbern, G. T., Working, R K., Engbers, C., Amantee, M. A. Comparative pharmacokinetics, tissue distribution and therapeutic effectiveness of cisplatin encapsulated in long circulating REGylated hposomes (SPl-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 1999, 43, 1—7. 

Use of dendrimers such as PAMAM, PPI and poly(ether hydro q lamine) (PEHAM) in drug deliveiy is mostly focused on cancer treatment. Dendrimers encapsulate anticancer drugs such as cisplatin and doxorubicin and agents for boron neutron capture therapy and photodynamic therapy. Cisplatin encapsulated dendrimers are reported to increase the bioavailability and selectivity of the drug on a solid tumor model which was provided by injection of B16F10 cells to C57 mice. ... 

To check the activity of cisplatin encapsulated HA-ODA nanoparticles, with and without PEG, we used the same resistant A549 tumours as previously. Mice treated with either cisplatin or HA-ODA/ cisplatin or HA-ODA/PEG/cisplatin nanoparticles showed tumour growth inhibition compared to the PBS treated group. In addition to showing slightly better efficacy compared to the other two at the early time points, the HA-ODA/cisplatin system also demonstrated some favourable safety properties compared to the other two, thus it was selected for the combination efficacy study [23]. 

Fig. 10.17 Carbon nanohoms encapsulate the chemotherapeutic agent cisplatin. TEM image (a) and inverse contrast TEM image of cisplatin loaded into the nanohoms (b). The drug is held at the closed end of the nanotube according to the image in (c) (Ajima et al., 2006)...

Hilder TA, Hill JM (2007) Modelling the encapsulation of the anticancer drug cisplatin into carbon nanotubes. Nanotechnology 18 Art. No. 275704. 

Thioethers form stable complexes, particularly if they are polydentate. Whereas only two sulfur atoms are coordinated in Ph2Pt(9S3),26 larger macrocycles, as in [Pt(12S4)]2+, can encapsulate the metal atom.27 The L-methionine complex (18-H-XII) is a metabolite of the anti-cancer drug cisplatin (see below).28... 

Preparations of liposomes via SCF processing are designated as critical fluid liposomes (CFLs). CFLs have successfully encapsulated hydrophobic drugs such as taxoids, camptothecins, doxorubicin, vincristine, and cisplatin. In addition, stable paclitaxel liposomes with a size of 150-250 nm were obtained. Aphios Co. s patent (US Patent 5,776,486) on Super-Fluids CFL describes a method that is useful for the nanoencapsulation of paclitaxel and campothecin in aqueous liposomal formulations called Taxosomes and Camposomes , respectively. 

Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM. Phase I and pharmacokinetic study of SPI-77, a hposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002 49(3) 201-10. 

Vail DM, Kurzman ID, Glawe PC, O Brien MG, Chun R, Garrett LD, Obradovich JE, Fred RM 3rd, Khanna C, Colbern GT, Working PK. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog a randomized multicenter clinical trial. Cancer Chemother Pharmacol 2002 50(2) 131-6. 

Fig. 10.20 Cytotoxicity of free and nanoparticle-encapsulated cisplatin to SKOV-3 adenocarcinoma cancer cells (2-h treatment) estimated with MTT Cell Proliferation Assay. Cisplatin dose, 0.25 ag/ml. Data represent mean SE (n = 3, P < 0.05) [97]...

Cisplatin is an effective and frequently used anti-cancer drug against a variety of solid tumours. The first trials of encapsulation faced the problem of low drug to lipid ratio due to the limited solubility of cisplatin resulting in low bioavailability. ... 

Hilder TA, HiU JM. Encapsulation of the anticancer drug cisplatin into nanotubes. In International conference on nanoscience and nanotechnology (ICONN 08) Febmary 2008. p. 109-12. 

---